Experimental mRNA therapy shows potential to combat antibiotic-resistant infections

national-institute-of-allergy-and-infectious-diseases-anC-NLa19D4-unsplash

Source: NIAID

Researchers have reported early success with a novel mRNA-based therapy designed to combat antibiotic-resistant bacteria. In preclinical studies, the therapy slowed bacterial growth, strengthened immune cell activity, and reduced lung tissue damage in models of multidrug-resistant pneumonia.

 Registered users, subscribers or members - SIGN IN

To continue reading this article

Membership

Included as a benefit

Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.

I AM A MEMBER

Find out more about how to join.

 

Register

FREE

Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.

REGISTER

 

Subscribe

3.75 per month / £35 annually

Get unlimited access to The Microbiologist.

SUBSCRIBE